Phreesia (PHR) 10-Q/A 10 Oct 19 2020 Q2 Quarterly report (amended) Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jul. 31, 2019	Sep. 06, 2019
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	false
Entity Registrant Name	Phreesia, Inc.
Entity Central Index Key	0001412408
Document Period End Date	Jul. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--01-31
Trading Symbol	PHR
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, State or Province	NY
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		35,761,374

Balance sheets

Balance sheets - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Current:
Cash and cash equivalents	$ 100,051,186	$ 1,542,514
Settlement assets	11,298,451	10,216,739
Accounts receivable, net of allowance for doubtful accounts of $722,758 and $517,707	16,787,723	16,109,035
Deferred contract acquisition costs	1,631,384	1,672,706
Prepaid expenses	6,019,043	3,339,788
Total current assets	135,787,787	32,880,782
Property and equipment, net of accumulated depreciation and amortization of $32,151,159 and $27,862,007	14,564,348	14,211,018
Capitalized internal-use software, net of accumulated amortization of $17,000,579 and $14,621,135	8,314,329	7,816,060
Deferred contract acquisition costs	1,447,079	1,521,400
Intangible assets, net of accumulated amortization of $152,269 and $33,269	1,317,731	1,436,731
Goodwill	250,190	250,190
Other assets	1,306,044	1,145,319
Total assets	162,987,508	59,261,500
Current:
Settlement obligations	11,298,451	10,216,739
Current portion of long-term debt	0	97,222
Current portion of capital leases	2,317,529	1,869,343
Accounts payable	10,979,101	4,159,994
Accrued expenses	8,250,017	5,097,868
Deferred revenue	5,782,499	6,487,910
Total current liabilities	38,627,597	27,929,076
Long-term debt, net of current portion	19,208,348	27,917,828
Capital leases, net of current portion	2,298,762	2,401,104
Warrant liability	0	5,497,627
Total liabilities	60,134,707	63,745,635
Commitments and contingencies (Note 12)
Redeemable preferred stock:
Redeemable preferred stock value	0	206,489,769
Stockholders' Equity (Deficit):
Common stock, $0.01 par value - 500,000,000 and 80,000,000 shares authorized as of July 31, 2019 and January 31, 2019, respectively; 35,759,355 and 1,994,721 shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively	357,594	19,947
Additional paid-in capital	380,875,148	0
Accumulated deficit	(278,379,941)	(210,993,851)
Total stockholders' equity (deficit)	102,852,801	(210,973,904)
Total Liabilities, Redeemable Preferred Stock and Stockholders' Equity (Deficit)	162,987,508	59,261,500
Senior A Redeemable Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	79,311,317
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	51,871,881
Junior Convertible Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	32,746,041
Redeemable Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	$ 0	$ 42,560,530

Balance sheets (Parenthetical)

Balance sheets (Parenthetical) - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Allowance for doubtful accounts	$ 722,758	$ 517,707
Accumulated depreciation and amortization, Property and equipment	32,151,159	27,862,007
Accumulated amortization, Capitalized internal-use software	17,000,579	14,621,135
Accumulated amortization, Intangible assets	$ 152,269	$ 33,269
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	80,000,000
Common stock, shares issued	35,759,355	1,994,721
Common stock, shares outstanding	35,759,355	1,994,721
Senior A Redeemable Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	14,500,000
Temporary equity, shares issued	0	13,674,365
Temporary equity, shares outstanding	0	13,674,365
Series B Redeemable Convertible Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	10,820,169
Temporary equity, shares issued	0	9,197,142
Temporary equity, shares outstanding	0	9,197,142
Junior Convertible Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	34,000,000
Temporary equity, shares issued	0	32,746,041
Temporary equity, shares outstanding	0	32,746,041
Redeemable Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	44,000,000
Temporary equity, shares issued	0	42,560,530
Temporary equity, shares outstanding	0	42,560,530

Statements of operations

Statements of operations - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Revenue:
Revenues	$ 30,816,168	$ 24,778,828	$ 59,125,902	$ 48,650,063
Expenses:
Cost of revenue (excluding depreciation and amortization)	4,210,203	3,603,669	8,205,913	6,826,864
Payment processing expense	7,100,675	5,326,634	14,050,009	10,916,466
Sales and marketing	8,120,137	6,528,930	15,821,750	12,775,934
Research and development	4,689,990	3,178,921	8,988,672	6,287,459
General and administrative	7,420,179	4,649,510	13,665,005	9,577,529
Depreciation	2,136,245	1,777,156	4,291,008	3,549,132
Amortization	1,279,106	962,889	2,498,444	1,875,526
Total expenses	34,956,535	26,027,708	67,520,801	51,808,909
Operating loss	(4,140,367)	(1,248,881)	(8,394,899)	(3,158,846)
Other income (expense)	327,421	138,819	(817,278)	(35,905)
Change in fair value of warrant liability	(2,883,851)	(593,215)	(3,306,959)	(884,168)
Interest income (expense)	(745,205)	(883,673)	(1,549,487)	(1,731,561)
Total other income (expense)	(3,301,635)	(1,338,069)	(5,673,724)	(2,651,634)
Loss before provision for income taxes	(7,442,002)	(2,586,950)	(14,068,623)	(5,810,481)
Provision for income taxes	(51,189)	0	(119,177)	0
Net loss	(7,493,191)	(2,586,950)	(14,187,800)	(5,810,481)
Preferred stock dividend paid	(14,955,101)	0	(14,955,101)	0
Accretion of redeemable preferred stock	(48,311,988)	(9,236,353)	(56,175,418)	(11,726,050)
Net loss attributable to common stockholders	$ (70,760,280)	$ (11,823,303)	$ (85,318,319)	$ (17,536,531)
Net loss per share attributable to common stockholders, basic and diluted	$ (10.42)	$ (6.66)	$ (19.20)	$ (9.99)
Weighted-average common shares outstanding, basic and diluted	6,793,363	1,776,559	4,443,155	1,755,268
Subscription And Related Services [Member]
Revenue:
Revenues	$ 14,003,676	$ 10,459,387	$ 26,686,304	$ 20,461,666
Payment Processing Fees [Member]
Revenue:
Revenues	11,664,507	9,173,665	23,221,797	18,405,192
Life Sciences [Member]
Revenue:
Revenues	$ 5,147,985	$ 5,145,776	$ 9,217,801	$ 9,783,205

Statements of redeemable prefer

Statements of redeemable preferred stock and stockholders' equity (deficit) - USD ($)	Total	Redeemable Series A Preferred Stock [Member]	Redeemable Series B Preferred Stock [Member]	Junior Convertible Preferred Stock [Member]	Redeemable Preferred Stock [Member]	Total Redeemable Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Beginning Balance at Jan. 31, 2018		$ 57,022,102	$ 43,962,340	$ 32,746,041	$ 42,560,530	$ 176,291,014
Beginning Balance at Jan. 31, 2018	$ (167,683,335)						$ 16,383	$ 0	$ (167,699,718)
Beginning Balance, Shares at Jan. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2018							1,638,331
Net loss	(3,223,531)								(3,223,531)
Stock-based compensation expense	251,697							251,697
Exercise of stock options	146,379						$ 1,316	145,063
Exercise of stock options Shares							131,560
Accretion of redeemable preferred stock		$ 1,405,838	$ 1,083,859			2,489,697
Accretion of redeemable preferred stock	(2,489,697)							(396,760)	(2,092,937)
Ending Balance at Apr. 30, 2018		$ 58,427,940	$ 45,046,199	$ 32,746,041	$ 42,560,530	178,780,711
Ending Balance at Apr. 30, 2018	(172,998,487)						$ 17,699	0	(173,016,186)
Ending Balance, Shares at Apr. 30, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance, Shares at Apr. 30, 2018							1,769,891
Beginning Balance at Jan. 31, 2018		$ 57,022,102	$ 43,962,340	$ 32,746,041	$ 42,560,530	176,291,014
Beginning Balance at Jan. 31, 2018	(167,683,335)						$ 16,383	0	(167,699,718)
Beginning Balance, Shares at Jan. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2018							1,638,331
Net loss	(5,810,481)
Ending Balance at Jul. 31, 2018		$ 65,389,066	$ 47,321,428	$ 32,746,041	$ 42,560,530	188,017,064
Ending Balance at Jul. 31, 2018	(184,557,671)						$ 17,860	0	(184,575,531)
Ending Balance, Shares at Jul. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance, Shares at Jul. 31, 2018							1,785,948
Beginning Balance at Apr. 30, 2018		$ 58,427,940	$ 45,046,199	$ 32,746,041	$ 42,560,530	178,780,711
Beginning Balance at Apr. 30, 2018	(172,998,487)						$ 17,699	0	(173,016,186)
Beginning Balance, Shares at Apr. 30, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Apr. 30, 2018							1,769,891
Net loss	(2,586,950)								(2,586,950)
Stock-based compensation expense	251,697							251,697
Exercise of stock options	12,422						$ 161	12,261
Exercise of stock options Shares							16,057
Accretion of redeemable preferred stock		$ 6,961,126	$ 2,275,228			9,236,353
Accretion of redeemable preferred stock	(9,236,353)							(263,958)	(8,972,395)
Ending Balance at Jul. 31, 2018		$ 65,389,066	$ 47,321,428	$ 32,746,041	$ 42,560,530	188,017,064
Ending Balance at Jul. 31, 2018	(184,557,671)						$ 17,860	0	(184,575,531)
Ending Balance, Shares at Jul. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance, Shares at Jul. 31, 2018							1,785,948
Beginning Balance at Jan. 31, 2019	206,489,769	$ 79,311,317	$ 51,871,881	$ 32,746,041	$ 42,560,530	206,489,769
Beginning Balance at Jan. 31, 2019	(210,973,904)						$ 19,947	0	(210,993,851)
Beginning Balance, Shares at Jan. 31, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2019							1,994,721
Net loss	(6,694,609)								(6,694,609)
Stock-based compensation expense	599,156							599,156
Exercise of stock options	37,035						$ 298	36,737
Exercise of stock options Shares							29,798
Issuance of common stock warrants	832,825							832,825
Accretion of redeemable preferred stock		$ 5,196,259	$ 2,667,171			7,863,430
Accretion of redeemable preferred stock	(7,863,430)							(1,468,718)	(6,394,712)
Ending Balance at Apr. 30, 2019		$ 84,507,576	$ 54,539,052	$ 32,746,041	$ 42,560,530	214,353,199
Ending Balance at Apr. 30, 2019	(224,062,927)						$ 20,245	0	(224,083,172)
Ending Balance, Shares at Apr. 30, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance, Shares at Apr. 30, 2019							2,024,519
Beginning Balance at Jan. 31, 2019	206,489,769	$ 79,311,317	$ 51,871,881	$ 32,746,041	$ 42,560,530	206,489,769
Beginning Balance at Jan. 31, 2019	(210,973,904)						$ 19,947	0	(210,993,851)
Beginning Balance, Shares at Jan. 31, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2019							1,994,721
Net loss	(14,187,800)
Ending Balance at Jul. 31, 2019	0		$ 0	$ 0	$ 0
Ending Balance at Jul. 31, 2019	102,852,801						$ 357,594	380,875,148	(278,379,941)
Ending Balance, Shares at Jul. 31, 2019			0	0	0
Ending Balance, Shares at Jul. 31, 2019							35,759,355
Beginning Balance at Apr. 30, 2019		$ 84,507,576	$ 54,539,052	$ 32,746,041	$ 42,560,530	214,353,199
Beginning Balance at Apr. 30, 2019	(224,062,927)						$ 20,245	0	(224,083,172)
Beginning Balance, Shares at Apr. 30, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Apr. 30, 2019							2,024,519
Net loss	(7,493,191)								(7,493,191)
Stock-based compensation expense	1,467,465							1,467,465
Exercise of stock options	41,167						$ 221	40,946
Exercise of stock options Shares							22,038
Accretion of redeemable preferred stock		$ 27,509,988	$ 20,802,000			48,311,988
Accretion of redeemable preferred stock	(48,311,988)							(1,508,410)	(46,803,578)
Payment of preferred stock dividends	(14,955,101)							(14,955,101)
Issuance of common stock in initial public offering, net of issuance costs of $6,083,648	124,697,602						$ 78,125	124,619,477
Issuance of common stock in initial public offering, net of issuance costs of $6,083,648 Shares							7,812,500
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	262,665,187	$ (112,017,564)	$ (75,341,052)	$ (32,746,041)	$ (42,560,530)	$ (262,665,187)	$ 253,115	262,412,072
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock Shares		(13,674,365)	(9,197,142)	(32,746,041)	(42,560,530)		25,311,535
Conversion and exercise of preferred stock warrants into common stock	8,804,587						$ 5,888	8,798,699
Conversion and exercise of preferred stock warrants into common stock Shares							588,763
Ending Balance at Jul. 31, 2019	0		$ 0	$ 0	$ 0
Ending Balance at Jul. 31, 2019	$ 102,852,801						$ 357,594	$ 380,875,148	$ (278,379,941)
Ending Balance, Shares at Jul. 31, 2019			0	0	0
Ending Balance, Shares at Jul. 31, 2019							35,759,355

Statements of redeemable pref_2

Statements of redeemable preferred stock and stockholders' equity (deficit) (Parenthetical) - USD ($)	Jul. 31, 2019	Jul. 22, 2019
Statement of Stockholders' Equity [Abstract]
Deferred Offering Costs	$ 6,083,648	$ 6,083,648

Statements of cash flows

Statements of cash flows - USD ($)	6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Cash flows from operating activities:
Net loss	$ (14,187,800)	$ (5,810,481)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,789,451	5,424,658
Stock-based compensation expense	2,066,621	503,394
Change in fair value of warrants liability	3,306,959	884,168
Amortization of debt discount	265,314	390,711
Loss on extinguishment of debt	1,072,813	0
Cost of Phreesia hardware purchased by customers	318,666	0
Changes in operating assets and liabilities
Accounts receivable	(678,688)	(1,135,300)
Prepaid expenses and other assets	(3,656,994)	(367,224)
Deferred contract acquisition costs	115,644	(163,838)
Accounts payable	4,548,149	875,157
Accrued expenses	3,329,991	(511,749)
Deferred revenue	(705,411)	855,596
Net cash provided by operating activities	2,584,715	945,093
Cash flows used in investing activities:
Capitalized internal-use software	(2,877,714)	(2,469,694)
Purchase of property and equipment	(2,754,478)	(2,390,158)
Net cash used in investing activities	(5,632,192)	(4,859,852)
Cash flows from financing activities:
Proceeds from IPO, net of underwriters' discounts and commissions	130,781,250	0
Proceeds from revolving line of credit	9,875,556	0
Payments of revolving line of credit	(17,675,556)	0
Proceeds from term loan	20,000,000	0
Repayment of term loan	(1,041,667)	(583,334)
Repayment of loan payable	(20,000,000)	0
Payment of preferred stock dividends	(14,955,101)	0
Payment on capital leases	(1,164,100)	(1,734,209)
Debt extinguishment costs	(300,000)	0
Debt issuance costs	(112,004)	0
Proceeds from issuance of common stock upon exercise of stock options	78,202	158,799
Payment of offering costs	(3,930,431)
Net cash (used in) provided by financing activities	101,556,149	(2,158,743)
Net increase in cash and cash equivalents	98,508,672	(6,073,503)
Cash and cash equivalents – beginning of period	1,542,514	10,502,789
Cash and cash equivalents – end of period	100,051,186	4,429,286
Supplemental information:
Property and equipment acquisitions through capital leases	1,509,945	983,275
Deferred issuance costs included in accounts payable and accrued expenses	1,957,966	0
Purchase of property and equipment included in accounts payable	698,579	0
Issurance of warrants related to debt	832,825	0
Cashless exercise of common stock warrants	1,918,782	0
Cash payments for:
Interest	$ 1,347,126	$ 1,317,613

Background and liquidity

Background and liquidity	6 Months Ended
	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	1. Background and liquidity (a) Background Phreesia, Inc. (the Company) is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform (the “Phreesia Platform”), the Company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and a leading payments solution for secure processing of patient payments. The Company’s Platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. The Company was formed in May 2005, and has its corporate headquarters in New York, and operations offices in Raleigh, North Carolina and Ottawa, and Canada. (b) Initial public offering On July 22, 2019, the Company closed its initial public offering (IPO), in which the Company issued and sold 7,812,500 shares of common stock at a public offering price of $18.00 per share, resulting in net proceeds of $130,781,250, after deducting underwriting discounts and commissions of $9,843,750 but before deducting deferred offering costs of $6,083,648. In addition to the shares of common stock sold by the Company upon the IPO, certain selling stockholders sold an aggregate of 2,868,923 shares of common stock as part of the IPO. Upon closing of the IPO, the Company’s outstanding shares of Senior A redeemable convertible preferred stock (Senior A Preferred), Senior B redeemable convertible preferred stock (Senior B Preferred, and together with the Senior A Preferred, the Senior Preferred), and the Junior convertible preferred stock (the Junior Preferred, and together with the Senior Preferred, the Convertible Preferred) automatically converted into shares of common stock and all of the outstanding shares of the Company’s redeemable preferred stock (Redeemable Preferred) were automatically extinguished and cancelled at the closing of the IPO (See Note 7). In addition, the Company’s warrants to purchase shares of Senior Preferred were converted into warrants to purchase shares of the Company’s common stock upon the closing of the IPO. Additionally, 588,763 shares of common stock were issued upon the cashless exercise of common stock warrants (See Note 10). Also, in connection with the IPO, the Company paid $14,955,101 in dividends to the Senior Preferred stockholders. Upon completion of the IPO on July 22, 2019, the Company filed an amended and restated certificate of incorporation to, among other things, state that the aggregate number of shares of stock that the Company is authorized to issue is 500,000,000 shares of common stock, par value $0.01 per share, and 20,000,000 shares of undesignated preferred stock, par value $0.01 per share. (c) Recapitalization The Company effected a 0.4551-for-1 (d) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of preferred stock and debt and most recently with proceeds from the IPO to fund its operations as well as sales of Company products in the normal course of business. Management believes that losses and negative cash flows will continue for at least the next year. Management believes that the Company’s cash and cash equivalents at July 31, 2019, along with cash generated in the normal course of business, and available borrowing capacity under its February 2019 Credit Facility (Note 6), are sufficient to fund its operations for at least the next 12 months. The Company will obtain additional financing if needed to successfully implement its long-term strategy. There can be no assurance that additional financing, if needed, can be obtained on terms acceptable to the Company. The ability of the Company to achieve successful operations will depend on, among other things, new business, the retention of customers, and the effectiveness of sales and marketing initiatives. The Company is subject to a number of risks similar to other companies in its stage of business life cycle, including dependence on key individuals, competition in the marketplace, and the need to fund future product and services development.

Basis of presentation

Basis of presentation	6 Months Ended
	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	2. Basis of presentation (a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and include the accounts of Phreesia, Inc. and its branch operation in Canada. (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively. (c) Unaudited interim financial statements The accompanying financial statements and the related footnote disclosures are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s interim financial position as of July 31, 2019 and the results of its operations and its cash flows for the periods ended July 31, 2019 and 2018. The results for the interim periods are not necessarily indicative of results to be expected for the full year, any other interim periods, or any future year or period. The Company’s management believes that the disclosures are adequate to make the information presented not misleading when read in conjunction with the audited financial statements and accompanying notes for the year ended January 31, 2019.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies	3. Summary of significant accounting policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended January 31, 2019. Since the date of those audited financial statements, there have been no changes to the Company’s significant accounting policies, including the status of recent accounting pronouncements, other than those detailed below. (a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results may differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use (b) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the three and six months ended July 31, 2019 and 2018. (c) New accounting pronouncements Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13). 2018-13 In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, internal-use In February 2016, the FASB issued ASU 2016-02, Leases right-of-use use-of-hindsight

Composition of certain financia

Composition of certain financial statement captions	6 Months Ended
	Jul. 31, 2019
Composition Of Certain Financial Statement [Abstract]
Composition of certain financial statement captions	4. Composition of certain financial statement captions (a) Accrued expenses Accrued expenses as of July 31, 2019 and January 31, 2019 are as follows: July 31, January 31, 2019 2019 Payment processing fees liability $ 2,308,694 $ 2,266,621 Commission and bonus 3,244,770 320,402 Accrued payment related to acquisition of Vital Score 350,000 350,000 Vacation 505,890 417,467 Other 1,840,663 1,743,378 Total $ 8,250,017 $ 5,097,868 (b) Property and equipment Property and equipment as of July 31, 2019 and January 31, 2019 are as follows: Useful Life July 31, January 31, (years) 2019 2019 PhreesiaPads and Arrivals Stations 3 $ 24,976,313 $ 22,746,783 Computer equipment 3 16,699,067 14,338,489 Computer software 3 2,166,014 2,166,015 Hardware development 3 1,024,357 1,024,357 Furniture and fixtures 7 678,985 646,708 Leasehold improvements 2 1,170,771 1,150,673 Total property and equipment $ 46,715,507 $ 42,073,025 Less accumulated depreciation and amortization (32,151,159 ) (27,862,007 ) Property and equipment — net $ 14,564,348 $ 14,211,018 Depreciation expense related to property and equipment amounted to $2,136,245 and $1,777,156 for the three months ended July 31, 2019 and 2018, respectively. Depreciation expense related to property and equipment amounted to $4,291,008 and $3,549,132 for the six months ended July 31, 2019 and 2018, respectively. Capital lease depreciation, included in depreciation expense, was $1,160,897 for the six months ended July 31, 2019. Assets under capital leases included in computer equipment were $11,745,433 and $10,235,489 as of July 31, 2019 and January 31, 2019. Accumulated amortization of assets under capital leases was $6,529,422 and $5,368,525 as of July 31, 2019 and January 31, 2019, respectively. (c) Capitalized internal use software For the three months ended July 31, 2019 and 2018, the Company capitalized $1,466,761 and $1,256,564, respectively, of costs related to the Phreesia Platform. For the six months ended July 31, 2019 and 2018, the Company capitalized $2,877,713 and $2,469,695 of costs related to the Phreesia Platform. During the three months ended July 31, 2019 and 2018, amortization expense of capitalized internal-use internal-use (d) Intangible assets The following presents the details of intangible assets as of July 31, 2019 and January 31, 2019. Useful Life July 31, January 31, (years) 2019 2019 Acquired technology gross carrying value 5 $ 490,000 $ 490,000 Customer relationship gross carrying value 7 980,000 980,000 Total intangible assets $ 1,470,000 $ 1,470,000 Less accumulated amortization (152,269 ) (33,269 ) Net carrying value $ 1,317,731 $ 1,436,731 The remaining useful life for acquired technology in years is 4.4 and 4.8 as of July 31, 2019 and January 31, 2019, respectively. The remaining useful life for customer relationships in years is 6.4 and 6.8 as of July 31, 2019 and January 31, 2019, respectively. Amortization expense associated with intangible assets amounted to $59,500 and $0 for the three months ended July 31, 2019 and 2018, respectively. Amortization expense associated with intangible assets amounted to $119,000 and $0 for the six months ended July 31, 2019 and 2018, respectively. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of July 31, 2019: 2020 (Remaining six months) $ 119,000 Years ending January 31, 2021 238,000 2022 238,000 2023 238,000 2024 224,301 2025 - thereafter 260,430 Total $ 1,317,731 (e) Deferred offering costs Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company’s IPO. Prior to the IPO, all deferred offering costs were capitalized in other assets on the accompanying balance sheet. Upon the closing of the IPO on July 22, 2019, $6,083,648 were recorded in stockholders’ deficit as a reduction of additional paid in capital. The Company recorded $539,560 of deferred offering costs within other assets on the accompanying balance sheet as of January 31, 2019. (f) Accounts receivable Accounts receivable as of July 31, 2019 and January 31, 2019 are as follows: July 31, January 31, 2019 2019 Billed $ 16,778,878 $ 15,990,218 Unbilled 731,603 635,924 Total accounts receivable, gross $ 17,510,481 $ 16,626,142 Less allowance for doubtful accounts (722,758 ) (517,107 ) Total accounts receivable $ 16,787,723 $ 16,109,035

Revenues

Revenues	6 Months Ended
	Jul. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue	5. Revenue The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s provider customers for access to the Phreesia Platform, payment processing fees based on patient payment volume processed through the Phreesia Platform, and from digital patient engagement revenue from life sciences companies to reach, educate and communicate with patients when they are most receptive and actively seeking care. The amount of subscription and related services revenue recorded pursuant to ASC 840 for the leasing of the Company’s self-service intake tablets and onsite kiosks was $1,506,003 and $1,105,521 for the three months ended July 31, 2019 and 2018, respectively. The amount of subscription and related services revenues recorded pursuant to ASC 840 for the leasing of the Company’s self-service intake tablets and onsite kiosks was $2,965,951 and $2,191,376 for the six months ended July 2019 and 2018, respectively. Contract balances The following table represents a rollforward of contract assets and contract liabilities: Contract assets Contract January 31, 2019 $ 635,924 $ 6,487,910 Amount transferred to receivables from contract assets (575,859 ) — Contract asset additions 671,539 — Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (7,665,170 ) Increases due to invoicing prior to satisfaction or performance obligations — 6,959,759 July 31, 2019 $ 731,604 $ 5,782,499 Cost to obtain a contract The Company capitalizes certain incremental costs to obtain customer contract and amortizes these costs over the life of the contracts. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $489,178 and $392,594 for the three months ended July 31, 2019 and 2018, respectively. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $973,578 and $763,453 for the six months ended July 31, 2019 and 2018, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented. The following table represents a rollforward of deferred contract acquisition costs: July 31, January 31, 2019 2019 Beginning balance $ 3,194,106 $ 2,333,578 Additions to deferred contract acquisition costs 857,935 2,500,183 Amortization of deferred contract acquisition costs (973,578 ) (1,639,655 ) Ending balance 3,078,463 3,194,106 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,631,384 1,672,706 Deferred contract acquisition costs, non current 1,447,079 1,521,400 Total deferred contract acquisition costs $ 3,078,463 $ 3,194,106

Debt

Debt	6 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Debt	6. Debt As of July 31, 2019 and January 31, 2019, the Company had the following outstanding loan balances: July 31, 2019 January 31, Term loan $ 20,000,000 $ 1,041,667 Line of credit — 7,800,000 Loan payable — 20,000,000 Total debt $ 20,000,000 $ 28,841,667 Less current maturities — (97,222 ) Less deferred financing costs (1,050,116 ) (995,959 ) Plus accrued interest 120,556 — Plus accrued final payment 137,908 169,342 Long term debt, net of current portion $ 19,208,348 $ 27,917,828 The Company had a loan facility with a commercial bank that provided for a term loan with an original principal amount of $3,500,000 and a $10,000,000 revolving line of credit, which was later increased to $20,000,000. The term loan was interest only, at a floating per annum rate equal to the Prime Rate as quoted by Wall Street Journal print edition less three-quarters of one percent (0.75%), for 12 months from the date of borrowing followed by 36 Borrowings under the revolving line of credit bore interest at the prime rate plus 1.00% and were limited to the greater of $ 20,000,000 line of credit were $5,441,326 and $971,370 for the six months ended July 31, 2019 and 2018, respectively. Interest expense under the revolving line of credit was $0 and $36,654 including amortization of deferred financing costs of $0 and $17,696, for the three months ended July 31, 2019 and 2018, respectively. Interest expense under the revolving line of credit was $166,254 and $73,100 including amortization of deferred financing costs of $12,843 and $35,392, for the six months ended July 31, 2019 and 2018, respectively. On November 7, 2016, the Company entered into a 5-year On February 28, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Loan and Security Agreement (the New Loan Agreement) that provides for a $20,000,000 term loan and a revolving credit facility with up to $25,000,000 of availability. The proceeds from the New Loan Agreement were used to repay in full the term loan, which had a balance of $1,041,667 as of January 31, 2019 and the $20,000,000 outstanding under the Loans Payable. The Company is also permitted to borrow an additional $10,000,000 term loan (the “Term Loan B Advance”) and, subject to the bank’s approval, another $15,000,000 (the “Term Loan C Advance”) prior to February 28, 2020. The term loans under the New Loan Agreement bear interest, which is payable monthly, at a floating rate equal to the bank’s prime rate plus 1.50% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the prime plus 0.75%. Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021. In addition to principal and interest payments due under the term loans, the Company is required to make a final payment to the lenders due upon the earlier of prepayment or maturity of the term loan, which is equal to 2.75% of the original principal amount. The Company accrues the estimated final payment fee using the effective interest method resulting in a charge to interest expense of $137,908 for the six months ended July 31, 2019. In connection with the New Loan Agreement, the Company issued warrants to the lenders to purchase an aggregate of 150,274 shares of common stock at an exercise price of $8.02 per share. The Warrants expire in February 2029. The fair value of the warrants of $832,825 was recorded as a debt discount and is being amortized to interest expense over the term of the new term loan and revolving credit facility. If the Company prepays the term loans prior to their respective scheduled maturities, it will also be required to make prepayment fees to the lenders equal to 3% if prepaid on or before the second anniversary of the Effective Date, 2% if prepaid after the second and on or before the third anniversary of funding or 1% if prepaid after the third anniversary of funding of the principal amounts borrowed. Interest expense related to the term loan under the New Loan Agreement was $396,680, including amortization of deferred financing fees of $38,902 for the three months ended July 31, 2019. Interest expense related to the term loan under the New Loan Agreement was $660,119, including amortization of deferred financing fees of $65,119 for the six months ended July 31, 2019. For the six months ended July 31, 2019, the effective interest rate on the term loan was 7.9%. The Company accounted for the settlement of the Loans Payable and the term loan as a debt extinguishment and recorded an expense of $1,072,813, which is included in other income (expense), and is comprised of the write-off 300,000 Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000,000 in the aggregate. The Company has $25,000,000 of availability as of July 31, 2019. Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75%, or 4.75%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual fee of $100,000 per year during the first three years of the facility and then $75,000 per year in years four and five. Interest expense related to the revolving credit facility under the new loan agreement was $213,826, including amortization of deferred financing fees of $31,646, for the three months ended July 31, 2019. Interest expense related to the revolving credit facility under the new loan agreement was $310,403, including amortization of deferred financing fees of $52,744, for the six months ended July 31, 2019. The Company is required to pay a fee of 0.15% per year for any unused availability and a termination fee of 1.50% if the revolving credit agreement is terminated prior to its scheduled maturity. The revolving credit facility is due five years from the Effective date, which is February 28, 2024. The Company’s obligations under the New Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The New Loan Agreement includes a financial covenant that requires the Company to achieve specified revenue levels, as defined, through January 31, 2020, after which time revenue levels for covenants purposes will be determined by the bank based on the Company’s forecast, subject to certain minimums. The Company is also required to maintain certain liquidity levels, as defined. The Company was in compliance with all covenants related to the New Loan Agreement as of July 31, 2019. The New Loan Agreement contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) significant judgments, orders or decrees for payments by the Company not covered by insurance; (vii) incorrectness of representations and warranties; (viii) incurrence of subordinated debt; (ix) revocation of governmental approvals necessary for the Company to conduct its business; and (x) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. As of July 31, 2019, the Company’s long-term debt is payable as follows: 2020 (Remaining six months) $ — Year ending January 31, 2021 — 2022 6,111,111 2023 6,666,667 2024 6,666,667 2025 - thereafter 555,555 Total long-term debt payments $ 20,000,000

Common stock

Common stock	6 Months Ended
	Jul. 31, 2019
Common Stock [Member]
Common Stock [Line Items]
Common stock	7. Common Stock The Company closed an IPO on July 22, 2019 and filed an amended and restated certificate of incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share. Upon completion of the IPO, the Company issued and sold 7,812,500 shares of common stock at an issuance price of $18.00 per share resulting in net proceeds of $130,781,250, after deducting underwriting discounts and commissions. In addition, all outstanding shares of Convertible Preferred stock converted into 25,311,515 shares of common stock (See Note 8) and the Company issued 588,763 shares of common stock as a result of the cashless exercise of warrants (See Note 10).

Preferred stock

Preferred stock	6 Months Ended
	Jul. 31, 2019
Preferred Stock [Abstract]
Preferred stock	8. Preferred stock Upon completion of the IPO on July 22, 2019, all of the Company’s then outstanding shares of Senior Preferred and Junior Preferred stock automatically converted into an aggregate of 25,311,515 shares of common stock and all of the Company’s then outstanding 42,560,530 shares of redeemable preferred stock were cancelled. As of July 31, 2019, there were no shares of convertible or redeemable preferred stock issued and outstanding. In connection with the IPO, the Company’s Amended and Restated Certificate of Incorporation became effective, which authorized 20,000,000 shares of undesignated preferred stock with a par value of $0.01 per share. Preferred stock dividends of $14,955,101 were paid in connection with the IPO.

Equity-based compensation

Equity-based compensation	6 Months Ended
	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Equity-based compensation	9. Equity-based compensation (a) Stock options In 2006, the Board of Directors adopted the Company’s 2006 Stock Option Plan, which provided for the issuance of options to purchase up to 151,548 shares of the Company’s common stock to officers, directors, employees, and consultants. Over the years, the Company amended the plan to increase the shares available for issuance. On October 14, 2014, the Company increased the number of shares available for issuance under the 2006 plan to 4,424,986. The 2006 Stock Option Plan expired in August 2017. In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan (as amended), which currently provides for the issuance of additional options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan, which replaced the 2018 Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee to make equity-based incentive awards to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this Plan is 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance will automatically increase on February 1, 2020 and each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). Options granted under the plans has a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year In June 2019, the Board of Directors also adopted the Company’s 2019 Employee Stock Purchase Plan (“The ESPP”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP is limited to 855,873 shares. The fair value of stock options is estimated on the date of the grant using the Black-Scholes option pricing model for each of the stock option awards granted. The Company historically has been a private company and lacked company-specific historical and implied volatility information for shares. Accordingly, expected volatility is based on the stock volatility for comparable publicly traded companies. The Company uses the simplified method as described in SAB 107 to estimate the expected life of stock options. Forfeitures are recorded when they occur. The risk-free rate is based on the U.S. Treasury yield curve at the time of the grant over the expected term of the stock option grants. The weighted average assumptions are provided below. For the three months ended For the six months ended July 31, July 31, July 31, July 31, 2019 2018 2019 2018 Risk-free interest rate 1.81 % — 2.18 % 2.66 % Expected dividends None — None None Expected term (in years) 6.25 — 6.25 6.25 Volatility 45.90 % — 45.14 % 40.00 % Weighted average fair market value of grants $ 5.54 — $ 4.93 $ 2.04 Stock option activity for the six months ended July 31, 2019 are as follows: Number of Weighted- Weighted- Aggregate Outstanding — January 31, 2019 5,055,505 $ 2.45 Granted in six months ended July 31, 2019 1,220,259 $ 8.63 Exercised (51,836 ) $ 1.51 Forfeited and expired (24,182 ) $ 4.18 Outstanding and expected to vest — July 31, 2019 6,199,746 $ 3.66 6.65 $ 50,628,007 Exercisable — July 31, 2019 4,014,845 $ 1.98 5.10 $ 39,765,476 Amount vested in six months ended July 31, 2019 406,421 $ 3.90 As of July 31, 2019, there are 2,139,683 shares are available for future grant pursuant to the newly adopted 2019 Plan as well as an additional 855,873 shares available for future grant pursuant to the newly adopted ESPP. The aggregate intrinsic value represents the total pre-tax in-the-money For the three months ended July 31, 2019 and 2018, the Company recorded stock-based compensation expense for stock options of $653,016 and $251,697, respectively. For the six months ended July 31, 2019 and 2018, the Company recorded stock-based compensation expense for stock options of $1,242,065 and $503,394, respectively. As of July 31, 2019, there is $7,732,078 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 3.2 The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense. (b) Restricted stock units On March 25, 2019 and June 20, 2019, the Company issued 390,794 and 58,589 stock units, respectively, to employees and directors that vest based on both a time-based condition and a performance-based condition. Pursuant to the time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The performance-based condition is based on a sale of the Company or an IPO, as defined. The restricted stock units expire in March 2026 and June 2026 respectively Upon completion of the Company’s IPO in July 2019, the Company immediately recognized the fair value of the vested units with the unvested portion recognized over the remaining service period. For the three and six months ended July 31, 2019, the Company recognized $814,448 and $824,555, respectively, in restricted stock unit compensation expense, with $3,700,364 remaining of total unrecognized compensation costs related to these awards as of July 31, 2019.

Stock warrants

Stock warrants	6 Months Ended
	Jul. 31, 2019
Warrant [Member]
Stock warrants	10. Stock warrants As of July 31, 2019 and January 31, 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase July 31, January 31, Exercise price Expiration Senior A Preferred — 116,232 $ 2.19 October 1, 2021 Senior A Preferred — 672,560 $ 3.00 November 1, 2026 Junior Preferred — 489,605 $ 0.01 September 5, 2020 Redeemable Preferred 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) — 1,636,641 Common stock — 166,952 $ 2.02 October 21, 2025 Common stock — 89,459 $ 3.49 November 1, 2026 Common stock 150,274 — $ 8.02 February 28, 2029 Common stock (converted from preferred stock warrants) 153,041 — $ 6.59 November 1, 2026 Total common stock (equity-classified) 303,315 256,411 The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance - January 31, 2019 256,411 1,636,411 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (685,168 ) (1,636,641 ) Balance - July 31, 2019 303,315 — The following table is a reconciliation of the warrant liability measured at fair value: Warrant Liability Balance at January 31, 2019 $ 5,497,627 Change in fair value of stock warrants six months ended July 31, 2019 3,306,959 Conversion of convertible preferred stock warrants (8,804,586 ) Balance at July 31, 2019 $ — Upon the closing of the IPO in July 2019, the Company’s outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase an aggregate of 581,798 shares of common stock. Upon the conversion, the Company reclassified the warrants to equity and recorded the then current value of the warrant liability on the date of reclassification to additional paid-in-capital. In July, the existing common stock warrant holders completed the cashless exercise of the warrants, resulting in the issuance of 256,411 shares of common stock whereby 25,919 shares of common stock were withheld by the Company to pay for the exercise price of the warrants.

Fair value measurements

Fair value measurements	6 Months Ended
	Jul. 31, 2019
Fair Value Disclosures [Abstract]
Fair value measurements	11. Fair value measurements The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The Company uses certain derivative financial instruments as part of its risk management strategy to reduce its foreign currency risk. The Company recognizes all derivatives on the balance sheet at fair value based on quotes obtained from financial institutions. The fair value of its foreign currency contracts as of July 31, 2019 and January 31, 2019 was a liability of $21,093 and $142,858, respectively, which are included in Accounts payable on the accompanying balance sheet. The fair value of the foreign currency contracts are considered Level 2 in the fair value hierarchy as of July 31, 2019 and January 31, 2019, respectively. Warrant Liability—The warrant liability is related to the warrants to purchase shares of preferred stock (see Note 10). Upon the closing of the IPO in July 2019, the warrants to purchase the Company’s convertible preferred stock were either converted into warrants to purchase common stock or subject to the cashless exercise into shares of common stock. As a result, the warrant liability was remeasured immediately prior to the closing date of the IPO and reclassified to stockholders’ equity (deficit). The Company used the Black-Scholes option-pricing model, which incorporated weighted-average inputs and assumptions, to value the warrant liability as of January 31, 2019 and as of the date of conversion. As of January 31, 2019, the warrant liability was valued at $5,497,627 as a non-current The Black-Scholes method and the following weighted-average inputs and assumptions was utilized to determine the fair value of the warrants as of January 31, 2019, pre-stock January 31, 2019 Series A Junior Redeemable Preferred Preferred Preferred Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6 % 2.5 % 2.5 % Expected volatility 45.1 % 45.1 % 45.1 % Dividend yield 0.0 % 0.0 % 0.0 % The Black Scholes Method and following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior Preferred Preferred Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9 % 1.9 % Expected volatility 45.9 % 45.9 % Dividend yield 0.0 % 0.0 % As the Company refinanced all of its debt on February 28, 2019 (see Note 6), it believes that the face value of its outstanding debt at July 31, 2019 and January 31, 2019 approximates fair value. The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the six months ended July 31, 2019 and 2018. The Company’s cash and cash equivalents includes money market funds which is measured at fair value. The Company consider these investments within Level 1 of the fair value hierarchy.

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jul. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	12. Commitments and contingencies (a) Operating and capital leases The Company leases its office premises in New York, North Carolina, and Ottawa under operating leases which expire on various dates through August 2022. The Company recognizes rent expense under such arrangements on a straight-line basis. Rent expense under such operating leases amounted to $458,732 and $449,630 for the three months ended July 31, 2019 and 2018, respectively. Rent expense under such operating leases amounted to $910,188 and $896,994 for the six months ended July 31, 2019 and 2018, respectively. As of July 31, 2019, the aggregate minimum net rental payments for non-cancelable 2020 (Remaining six months) $ 870,963 Year ending January 31, 2021 1,751,115 2022 744,894 2023 224,532 Total operating lease payments $ 3,591,504 During the six months ended July 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 2020 (Remaining six months) $ 1,157,957 Year ending January 31, 2021 2,319,143 2022 1,536,429 2023 138,054 Total capital lease payments $ 5,151,583 Less amounts representing interest (535,292 ) Total capital lease payments, net of interest 4,616,291 Less current portion (2,317,529 ) Total capital lease payments, net of interest and current portion $ 2,298,762 Interest expense related to capital leases was $88,080 and $61,097 for the three months ended July 31, 2019 and 2018, respectively. Interest expense related to capital leases was $151,050 and $110,070 for the six months ended July 31, 2019 and 2018, respectively. (b) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.

Income taxes

Income taxes	6 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes	13. Income taxes The effective tax rate is 0% and 0% in the six months ended July 31, 2019 and 2018, respectively. The difference between the U.S. Statutory rate of 21% and the effective tax rate is primarily due to the change in valuation allowance. The Company has recorded a full valuation allowance against its deferred tax assets at July 31, 2019 and January 31, 2019.

Net loss per share attributable

Net loss per share attributable to common stockholders	6 Months Ended
	Jul. 31, 2019
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	14. Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three months ended July 31, Six months ended July 31, 2019 2018 2019 2018 Numerator: Net loss $ (7,493,191 ) $ (2,586,950 ) $ (14,187,800 ) $ (5,810,481 ) Preferred stock dividend paid (14,955,101 ) — (14,955,101 ) — Accretion of redeemable preferred stock (48,311,988 ) (9,236,353 ) (56,175,418 ) (11,726,050 ) Net loss attributable to common stockholders $ (70,760,280 ) $ (11,823,303 ) $ (85,318,319 ) $ (17,536,531 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 6,793,363 1,776,559 4,443,155 1,755,268 Net loss attributable to common stockholders, basic and diluted $ (10.42 ) $ (6.66 ) $ (19.20 ) $ (9.99 ) The Company’s potential dilutive securities, which include Convertible Preferred, stock options, restricted stock units and outstanding warrants to purchase shares of common and preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: July 31, 2019 2018 Redeemable convertible preferred stock (as-converted to common stock) — 25,311,535 Stock options to purchase common stock and restricted stock units 6,649,129 5,089,974 Warrants to purchase convertible preferred stock — 581,798 Warrants to purchase common stock 303,315 256,411 6,952,444 31,239,718

Related party transactions

Related party transactions	6 Months Ended
	Jul. 31, 2019
Related Party Transactions [Abstract]
Related party transactions	15. Related party transactions The Company recognized revenue totaling approximately $1,372,000 and $1,219,000 from an affiliate of a stockholder of the Company for the three months ended July 31, 2019 and 2018, respectively. The Company recognized revenue totaling approximately $2,876,000 and $2,578,000 from an affiliate of a stockholder of the Company for the six months ended July 31, 2019 and 2018, respectively. Accounts receivable from the affiliate totaled approximately $891,000 and $598,000 as of July 31, 2019 and January 31, 2019, respectively.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Basis of presentation	(a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and include the accounts of Phreesia, Inc. and its branch operation in Canada.
Fiscal Period	(b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively.
Use of estimates	(a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results may differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use
Concentrations of credit risk	(b) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the three and six months ended July 31, 2019 and 2018.
New accounting pronouncements	(c) New accounting pronouncements Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13). 2018-13 In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, internal-use In February 2016, the FASB issued ASU 2016-02, Leases right-of-use use-of-hindsight

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	6 Months Ended
	Jul. 31, 2019
Composition Of Certain Financial Statement [Abstract]
Schedule of accrued liabilities	Accrued expenses as of July 31, 2019 and January 31, 2019 are as follows: July 31, January 31, 2019 2019 Payment processing fees liability $ 2,308,694 $ 2,266,621 Commission and bonus 3,244,770 320,402 Accrued payment related to acquisition of Vital Score 350,000 350,000 Vacation 505,890 417,467 Other 1,840,663 1,743,378 Total $ 8,250,017 $ 5,097,868
Schedule of property and equipment	Property and equipment as of July 31, 2019 and January 31, 2019 are as follows: Useful Life July 31, January 31, (years) 2019 2019 PhreesiaPads and Arrivals Stations 3 $ 24,976,313 $ 22,746,783 Computer equipment 3 16,699,067 14,338,489 Computer software 3 2,166,014 2,166,015 Hardware development 3 1,024,357 1,024,357 Furniture and fixtures 7 678,985 646,708 Leasehold improvements 2 1,170,771 1,150,673 Total property and equipment $ 46,715,507 $ 42,073,025 Less accumulated depreciation and amortization (32,151,159 ) (27,862,007 ) Property and equipment — net $ 14,564,348 $ 14,211,018
Schedule of intangible assets	The following presents the details of intangible assets as of July 31, 2019 and January 31, 2019. Useful Life July 31, January 31, (years) 2019 2019 Acquired technology gross carrying value 5 $ 490,000 $ 490,000 Customer relationship gross carrying value 7 980,000 980,000 Total intangible assets $ 1,470,000 $ 1,470,000 Less accumulated amortization (152,269 ) (33,269 ) Net carrying value $ 1,317,731 $ 1,436,731
Schedule of estimated amortization expense for intangible assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of July 31, 2019: 2020 (Remaining six months) $ 119,000 Years ending January 31, 2021 238,000 2022 238,000 2023 238,000 2024 224,301 2025 - thereafter 260,430 Total $ 1,317,731
Schedule of accounts receivable	Accounts receivable as of July 31, 2019 and January 31, 2019 are as follows: July 31, January 31, 2019 2019 Billed $ 16,778,878 $ 15,990,218 Unbilled 731,603 635,924 Total accounts receivable, gross $ 17,510,481 $ 16,626,142 Less allowance for doubtful accounts (722,758 ) (517,107 ) Total accounts receivable $ 16,787,723 $ 16,109,035

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Jul. 31, 2019
Revenue from Contract with Customer [Abstract]
Rollforward of contract assets and contract liabilities	The following table represents a rollforward of contract assets and contract liabilities: Contract assets Contract January 31, 2019 $ 635,924 $ 6,487,910 Amount transferred to receivables from contract assets (575,859 ) — Contract asset additions 671,539 — Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (7,665,170 ) Increases due to invoicing prior to satisfaction or performance obligations — 6,959,759 July 31, 2019 $ 731,604 $ 5,782,499
Deferred contract acquisition costs	The following table represents a rollforward of deferred contract acquisition costs: July 31, January 31, 2019 2019 Beginning balance $ 3,194,106 $ 2,333,578 Additions to deferred contract acquisition costs 857,935 2,500,183 Amortization of deferred contract acquisition costs (973,578 ) (1,639,655 ) Ending balance 3,078,463 3,194,106 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,631,384 1,672,706 Deferred contract acquisition costs, non current 1,447,079 1,521,400 Total deferred contract acquisition costs $ 3,078,463 $ 3,194,106

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of July 31, 2019 and January 31, 2019, the Company had the following outstanding loan balances: July 31, 2019 January 31, Term loan $ 20,000,000 $ 1,041,667 Line of credit — 7,800,000 Loan payable — 20,000,000 Total debt $ 20,000,000 $ 28,841,667 Less current maturities — (97,222 ) Less deferred financing costs (1,050,116 ) (995,959 ) Plus accrued interest 120,556 — Plus accrued final payment 137,908 169,342 Long term debt, net of current portion $ 19,208,348 $ 27,917,828
Schedule of maturities of long-term debt	As of July 31, 2019, the Company’s long-term debt is payable as follows: 2020 (Remaining six months) $ — Year ending January 31, 2021 — 2022 6,111,111 2023 6,666,667 2024 6,666,667 2025 - thereafter 555,555 Total long-term debt payments $ 20,000,000

Equity-based compensation (Tabl

Equity-based compensation (Tables) - Stock Option [Member]	6 Months Ended
	Jul. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of weighted average assumptions	The weighted average assumptions are provided below. For the three months ended For the six months ended July 31, July 31, July 31, July 31, 2019 2018 2019 2018 Risk-free interest rate 1.81 % — 2.18 % 2.66 % Expected dividends None — None None Expected term (in years) 6.25 — 6.25 6.25 Volatility 45.90 % — 45.14 % 40.00 % Weighted average fair market value of grants $ 5.54 — $ 4.93 $ 2.04
Schedule of stock option activity	Stock option activity for the six months ended July 31, 2019 are as follows: Number of Weighted- Weighted- Aggregate Outstanding — January 31, 2019 5,055,505 $ 2.45 Granted in six months ended July 31, 2019 1,220,259 $ 8.63 Exercised (51,836 ) $ 1.51 Forfeited and expired (24,182 ) $ 4.18 Outstanding and expected to vest — July 31, 2019 6,199,746 $ 3.66 6.65 $ 50,628,007 Exercisable — July 31, 2019 4,014,845 $ 1.98 5.10 $ 39,765,476 Amount vested in six months ended July 31, 2019 406,421 $ 3.90

Stock warrants (Tables)

Stock warrants (Tables)	6 Months Ended
	Jul. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrants to purchase common and preferred stock outstanding	As of July 31, 2019 and January 31, 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase July 31, January 31, Exercise price Expiration Senior A Preferred — 116,232 $ 2.19 October 1, 2021 Senior A Preferred — 672,560 $ 3.00 November 1, 2026 Junior Preferred — 489,605 $ 0.01 September 5, 2020 Redeemable Preferred 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) — 1,636,641 Common stock — 166,952 $ 2.02 October 21, 2025 Common stock — 89,459 $ 3.49 November 1, 2026 Common stock 150,274 — $ 8.02 February 28, 2029 Common stock (converted from preferred stock warrants) 153,041 — $ 6.59 November 1, 2026 Total common stock (equity-classified) 303,315 256,411
Schedule of summarizes the activity for the company's warrants	The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance - January 31, 2019 256,411 1,636,411 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (685,168 ) (1,636,641 ) Balance - July 31, 2019 303,315 —
Schedule of reconciliation of the warrant liability measured at fair value	The following table is a reconciliation of the warrant liability measured at fair value: Warrant Liability Balance at January 31, 2019 $ 5,497,627 Change in fair value of stock warrants six months ended July 31, 2019 3,306,959 Conversion of convertible preferred stock warrants (8,804,586 ) Balance at July 31, 2019 $ —

Fair value measurements (Tables

Fair value measurements (Tables)	6 Months Ended
	Jul. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of weighted-average inputs and assumptions	The Black-Scholes method and the following weighted-average inputs and assumptions was utilized to determine the fair value of the warrants as of January 31, 2019, pre-stock January 31, 2019 Series A Junior Redeemable Preferred Preferred Preferred Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6 % 2.5 % 2.5 % Expected volatility 45.1 % 45.1 % 45.1 % Dividend yield 0.0 % 0.0 % 0.0 %
Schedule of measure the fair market value of the warrant liability	The Black Scholes Method and following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior Preferred Preferred Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9 % 1.9 % Expected volatility 45.9 % 45.9 % Dividend yield 0.0 % 0.0 %

Commitments and contingencies (

Commitments and contingencies (Tables)	6 Months Ended
	Jul. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of aggregate minimum net rental payments	As of July 31, 2019, the aggregate minimum net rental payments for non-cancelable 2020 (Remaining six months) $ 870,963 Year ending January 31, 2021 1,751,115 2022 744,894 2023 224,532 Total operating lease payments $ 3,591,504
Schedule of minimum lease payments	During the six months ended July 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 2020 (Remaining six months) $ 1,157,957 Year ending January 31, 2021 2,319,143 2022 1,536,429 2023 138,054 Total capital lease payments $ 5,151,583 Less amounts representing interest (535,292 ) Total capital lease payments, net of interest 4,616,291 Less current portion (2,317,529 ) Total capital lease payments, net of interest and current portion $ 2,298,762

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	6 Months Ended
	Jul. 31, 2019
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three months ended July 31, Six months ended July 31, 2019 2018 2019 2018 Numerator: Net loss $ (7,493,191 ) $ (2,586,950 ) $ (14,187,800 ) $ (5,810,481 ) Preferred stock dividend paid (14,955,101 ) — (14,955,101 ) — Accretion of redeemable preferred stock (48,311,988 ) (9,236,353 ) (56,175,418 ) (11,726,050 ) Net loss attributable to common stockholders $ (70,760,280 ) $ (11,823,303 ) $ (85,318,319 ) $ (17,536,531 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 6,793,363 1,776,559 4,443,155 1,755,268 Net loss attributable to common stockholders, basic and diluted $ (10.42 ) $ (6.66 ) $ (19.20 ) $ (9.99 )
Schedule of shares excluded from computation of diluted net loss per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: July 31, 2019 2018 Redeemable convertible preferred stock (as-converted to common stock) — 25,311,535 Stock options to purchase common stock and restricted stock units 6,649,129 5,089,974 Warrants to purchase convertible preferred stock — 581,798 Warrants to purchase common stock 303,315 256,411 6,952,444 31,239,718

Background and liquidity - Addi

Background and liquidity - Additional Information (Detail)	Jul. 22, 2019USD ($)$ / sharesshares	Jul. 03, 2019	Jul. 31, 2019USD ($)$ / sharesshares	Jul. 31, 2018USD ($)	Jul. 31, 2019USD ($)$ / sharesshares	Jul. 31, 2018USD ($)	Jan. 31, 2019$ / sharesshares
Background And Liquidity [Line Items]
Proceeds from issuance initial public offering					$ 130,781,250	$ 0
Deferred offering costs					3,930,431
Payments of preferred stock dividends			$ 14,955,101	$ 0	$ 14,955,101	$ 0
Common stock authorized | shares	500,000,000		500,000,000		500,000,000		80,000,000
Common stock par value | $ / shares	$ 0.01		$ 0.01		$ 0.01		$ 0.01
Preferred stock authorized | shares	20,000,000
Preferred stock par value | $ / shares	$ 0.01
Stockholder equity reverse stock splits		0.4551-for-1
Reverse stock splits shares combined		2.1973
Year formed					2005
Minimum [Member]
Background And Liquidity [Line Items]
Number of months the company have sufficient to fund its operations					12 months
IPO [Member]
Background And Liquidity [Line Items]
Stock issued during period initial public offering | shares	7,812,500
Share price | $ / shares	$ 18
Proceeds from issuance initial public offering	$ 130,781,250
Underwriting discounts and commission	9,843,750
Deferred offering costs	$ 6,083,648
Conversion and exercise of preferred stock warrants | shares	588,763
Payments of preferred stock dividends	$ 14,955,101				$ 14,955,101
Common stock authorized | shares	500,000,000
Common stock par value | $ / shares	$ 0.01
IPO [Member] | Stockholders [Member]
Background And Liquidity [Line Items]
Stock issued during period initial public offering | shares	2,868,923

Composition of certain financ_3

Composition of certain financial statement captions - Schedule of Accrued Liabilities (Detail) - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Accrued Expenses [Abstract]
Payment processing fees liability	$ 2,308,694	$ 2,266,621
Commission and bonus	3,244,770	320,402
Accrued payment related to acquisition of Vital Score	350,000	350,000
Vacation	505,890	417,467
Other	1,840,663	1,743,378
Total	$ 8,250,017	$ 5,097,868

Composition of certain financ_4

Composition of certain financial statement captions - Schedule of Property and Equipment (Detail) - USD ($)	6 Months Ended
	Jul. 31, 2019	Jan. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 46,715,507	$ 42,073,025
Less accumulated depreciation and amortization	(32,151,159)	(27,862,007)
Property and equipment — net	14,564,348	14,211,018
PhreesiaPads and Arrivals Stations [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 24,976,313	22,746,783
Property and equipment Useful Life	3 years
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 16,699,067	14,338,489
Property and equipment Useful Life	3 years
Computer software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 2,166,014	2,166,015
Property and equipment Useful Life	3 years
Hardware development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 1,024,357	1,024,357
Property and equipment Useful Life	3 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 678,985	646,708
Property and equipment Useful Life	7 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 1,170,771	$ 1,150,673
Property and equipment Useful Life	2 years

Composition of certain financ_5

Composition of certain financial statement captions - Schedule Of Finite Lived Intangible Assets (Detail) - USD ($)	6 Months Ended
	Jul. 31, 2019	Jan. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 1,470,000	$ 1,470,000
Less accumulated amortization	(152,269)	(33,269)
Net carrying value	1,317,731	1,436,731
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 490,000	490,000
Finite-lived intangible asset, useful life	5 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 980,000	$ 980,000
Finite-lived intangible asset, useful life	7 years

Composition of certain financ_6

Composition of certain financial statement captions - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (Remaining six months)	$ 119,000
2021	238,000
2022	238,000
2023	238,000
2024	224,301
2025 - thereafter	260,430
Net carrying value	$ 1,317,731	$ 1,436,731

Composition of certain financ_7

Composition of certain financial statement captions - Schedule Of Accounts Notes Loans And Financing Receivable (Detail) - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Accounts Receivable Additional Disclosures [Abstract]
Billed	$ 16,778,878	$ 15,990,218
Unbilled	731,603	635,924
Total accounts receivable, gross	17,510,481	16,626,142
Less allowance for doubtful accounts	(722,758)	(517,707)
Total accounts receivable	$ 16,787,723	$ 16,109,035

Composition of certain financ_8

Composition of certain financial statement captions - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jan. 31, 2019	Jul. 31, 2018	Jul. 22, 2019
Composition Of Certain Financial Statement [Line Items]
Depreciation	$ 2,136,245	$ 1,777,156	$ 4,291,008		$ 3,549,132
Capitalized computer software net	8,314,329		8,314,329	$ 7,816,060
Amortization of intangible assets	59,500	0	119,000		0
Deferred offering costs	6,083,648		6,083,648			$ 6,083,648
Accumulated amortization of capital lease assets	6,529,422		6,529,422	5,368,525
Capital Leased Assets, Gross	11,745,433		11,745,433	10,235,489
Phreesia Platform Software [Member]
Composition Of Certain Financial Statement [Line Items]
Capitalized cost of computer software	1,466,761	1,256,564	2,877,713		2,469,695
Capitalized computed software amortization	1,219,605	$ 962,889	2,379,443		$ 1,875,526
Capitalized computer software net	8,314,329		$ 8,314,329	$ 7,816,060
Acquired Technology [Member]
Composition Of Certain Financial Statement [Line Items]
Remaining useful life of acquired intangible assets			4 years 4 months 24 days	4 years 9 months 18 days
Customer Relationships [Member]
Composition Of Certain Financial Statement [Line Items]
Remaining useful life of finite lived intangible assets			6 years 4 months 24 days	6 years 9 months 18 days
Depreciation [Member]
Composition Of Certain Financial Statement [Line Items]
Capital leases depreciation			$ 1,160,897
Other Assets [Member]
Composition Of Certain Financial Statement [Line Items]
Deferred offering costs	$ 0		$ 0	$ 539,560

Revenues - Schedule Of Rollforw

Revenues - Schedule Of Rollforward of contract assets and contract liabilities (Detail)	6 Months Ended
	Jul. 31, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Beginning balance - Contract assets (unbilled accounts receivable)	$ 635,924
Amount transferred to receivables from contract assets	(575,859)
Contract asset additions	671,539
Ending balance - Contract assets (unbilled accounts receivable)	731,604
Beginning balance - Contract liabilities (deferred revenue)	6,487,910
Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period	(7,665,170)
Increases due to invoicing prior to satisfaction or performance obligations	6,959,759
Ending balance - Contract liabilities (deferred revenue)	$ 5,782,499

Revenues - Schedule Of Deferred

Revenues - Schedule Of Deferred contract acquisition costs (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jul. 31, 2019	Jan. 31, 2019	Jul. 31, 2019	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 3,194,106	$ 2,333,578
Additions to deferred contract acquisition costs	857,935	2,500,183
Amortization of deferred contract acquisition costs	(973,578)	(1,639,655)
Ending balance	3,078,463	3,194,106
Deferred contract acquisition costs, current (to be amortized in next 12 months)			$ 1,631,384	$ 1,672,706
Deferred contract acquisition costs, non current			1,447,079	1,521,400
Total deferred contract acquisition costs	$ 3,194,106	$ 3,194,106	$ 3,078,463	$ 3,194,106

Revenues - Additional Informati

Revenues - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018	Jan. 31, 2019
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	$ 30,816,168	$ 24,778,828	$ 59,125,902	$ 48,650,063
Capitalized contract cost, amortization			973,578		$ 1,639,655
Selling and Marketing Expense [Member]
Revenue From Contract With Customer [Line Items]
Capitalized contract cost, amortization	489,178	392,594	973,578	763,453
Subscription And Related Services [Member]
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	14,003,676	10,459,387	26,686,304	20,461,666
Subscription And Related Services [Member] | Onsite kiosks [Member]
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	$ 1,506,003	$ 1,105,521	$ 2,965,951	$ 2,191,376

Debt - Schedule Of Outstanding

Debt - Schedule Of Outstanding loan balances (Detail) - USD ($)	Jul. 31, 2019	Jan. 31, 2019	Nov. 07, 2016
Debt Instrument [Line Items]
Long term debt gross	$ 20,000,000	$ 28,841,667
Less current maturities	0	97,222
Less deferred financing costs	(1,050,116)	(995,959)
Plus accrued interest	120,556
Plus accrued final payment	137,908	169,342
Long term debt, net of current portion	19,208,348	27,917,828
Term Loan [Member]
Debt Instrument [Line Items]
Long term debt gross	$ 20,000,000	1,041,667
Line of Credit [Member]
Debt Instrument [Line Items]
Long term debt gross		7,800,000
Loans Payable [Member]
Debt Instrument [Line Items]
Long term debt gross		$ 20,000,000	$ 20,000,000

Debt - Schedule of long-term de

Debt - Schedule of long-term debt maturities (Detail)	Jul. 31, 2019USD ($)
Debt Disclosure [Abstract]
2020 (Remaining six months)	$ 0
2021	0
2022	6,111,111
2023	6,666,667
2024	6,666,667
2025 - thereafter	555,555
Total long-term debt payments	$ 20,000,000

Debt - Additional information (

Debt - Additional information (Detail) - USD ($)	Jul. 22, 2019	Feb. 28, 2019	Jan. 31, 2019	May 31, 2017	Nov. 07, 2016	Feb. 28, 2019	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Debt [Line Items]
Final fee charged to interest			$ 169,342				$ 137,908		$ 137,908
Repayments of revolving credit	$ 17,675,556								17,675,556	$ 0
Long term debt gross			28,841,667				$ 20,000,000		$ 20,000,000
Number of securities called by warrants							428,757		428,757
Write-off of deferred financing costs									$ 772,813
Extinguishment and modification fee									(1,072,813)	0
Debt issuance costs									$ 112,004	0
Debt instrument fee percentage									5%
Prepayment fee							$ 300,000		$ 300,000
Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Number of securities called by warrants		150,274				150,274
Exercise price		$ 8.02				$ 8.02
Prepayment fee percentage		3.00%				3.00%
Prepayment fee percentage		2.00%				2.00%
Prepayment fee percentage		1.00%				1.00%
Warrants fair value disclosure		$ 832,825				$ 832,825
Warrants expiration period		2029-02
Loans Payable [Member]
Debt [Line Items]
Maximum borrowing capacity					$ 10,000,000
Interest expense							0	$ 592,053	168,056	1,165,773
Amortization of financing costs							0	$ 29,831	0	$ 59,662
Effective interest rate percentage								13.60%		13.60%
Expiration period					5 years
Proceeds from lines of credit				$ 10,000,000
Stated interest percentage					11.00%
Loan agreement, term					principal due in 30 equal installments beginning in June 2019.
Long term debt gross			20,000,000		$ 20,000,000
Term Loan [Member]
Debt [Line Items]
Maximum borrowing capacity			$ 3,500,000
Interest rate description						Prime Rate as quoted by Wall Street Journal print edition less three-quarters of one percent (0.75%)
Final fee charged to interest							0	$ 6,904	5,658	$ 13,809
Interest expense							0	24,475	15,873	50,282
Amortization of financing costs							0	$ 5,865	$ 4,806	$ 11,730
Effective interest rate percentage								6.30%		6.30%
Description of variable rate basis			Prime Rate was 5.50%
Expiration period									36 months
Long term debt gross			$ 1,041,667				20,000,000		$ 20,000,000
Prepayment fee							175,000		175,000
Term Loan [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Final fee charged to interest		$ 137,908				$ 137,908
Interest expense							396,680		660,119
Amortization of financing costs							$ 38,902		$ 65,119
Effective interest rate percentage							7.90%		7.90%
Description of variable rate basis		prime rate plus 1.50%
Loan agreement, term		Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021.
Long term debt gross		$ 20,000,000	$ 1,041,667			20,000,000
Description of variable rate basis		prime plus 0.75%
Unused capacity fee percentage		0.15%
Termination fee percentage		1.50%
Debt instrument fee percentage		2.75%
Term Loan B Advance [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Maximum borrowing capacity		$ 10,000,000				10,000,000
Term Loan C Advance [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Maximum borrowing capacity		15,000,000				15,000,000
Revolving Credit Facility [Member]
Debt [Line Items]
Interest expense							$ 0	$ 36,654	$ 166,254	$ 73,100
Amortization of financing costs							0	$ 17,696	$ 12,843	35,392
Description of variable rate basis									prime rate plus 1.00%
Maturity date									Nov. 30, 2019
Weighted-average borrowings outstanding									$ 5,441,326	$ 971,370
Revolving line of credit					$ 10,000,000		20,000,000		$ 20,000,000
Revolving Credit Facility [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Maximum borrowing capacity		25,000,000				25,000,000
Interest rate description									Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75%, or 4.75%.
Interest expense							213,826		$ 310,403
Amortization of financing costs							31,646		$ 52,744
Maturity date									Feb. 28, 2024
Expiration period									5 years
Borrowing capacity decription									Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000,000 in the aggregate.
Annual fee per year during the first three years									$ 100,000
Annual fee per year in years four and five									75,000
Revolving line of credit		$ 25,000,000				$ 25,000,000	$ 25,000,000		$ 25,000,000

Common Stock - Additional infor

Common Stock - Additional information (Detail) - USD ($)	Jul. 22, 2019	Jul. 31, 2019	Jul. 31, 2018	Jan. 31, 2019
Class of Stock [Line Items]
Common stock authorized	500,000,000	500,000,000		80,000,000
Common stock par value	$ 0.01	$ 0.01		$ 0.01
Proceeds from proceeds from issuance intial public offering		$ 130,781,250	$ 0
IPO [Member]
Class of Stock [Line Items]
Common stock authorized	500,000,000
Common stock par value	$ 0.01
Stock issued during period initial public offering	7,812,500
Share price	$ 18
Proceeds from proceeds from issuance intial public offering	$ 130,781,250
Convertible preferred stock converted	588,763
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock converted	25,311,515

Preferred stock - Additional in

Preferred stock - Additional information (Detail) - USD ($)	Jul. 22, 2019	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018	Apr. 30, 2019	Jan. 31, 2019	Apr. 30, 2018	Jan. 31, 2018
Preferred Stock [Line Items]
Aggregate of common stock		35,759,355		35,759,355			1,994,721
Preferred stock authorized	20,000,000
Preferred stock par value	$ 0.01
Dividend paid		$ 14,955,101	$ 0	$ 14,955,101	$ 0
IPO [Member]
Preferred Stock [Line Items]
Aggregate of common stock	25,311,515
Dividend paid	$ 14,955,101			$ 14,955,101
Junior Convertible Preferred Stock [Member]
Preferred Stock [Line Items]
Temporary equity cancelled		(32,746,041)
Temporary equity, shares outstanding		0	32,746,041	0	32,746,041	32,746,041	32,746,041	32,746,041	32,746,041
Temporary equity, shares issued		0		0			32,746,041
Redeemable Preferred Stock [Member]
Preferred Stock [Line Items]
Temporary equity cancelled	(42,560,530)	(42,560,530)
Temporary equity, shares outstanding		0	42,560,530	0	42,560,530	42,560,530	42,560,530	42,560,530	42,560,530
Temporary equity, shares issued		0		0			42,560,530

Equity-based compensation - Wei

Equity-based compensation - Weighted Average Assumptions (Detail) - Stock Option [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.81%	0.00%	2.18%	2.66%
Expected dividends	$ 0	$ 0	$ 0	$ 0
Expected term (in years)	6 years 3 months	0 years	6 years 3 months	6 years 3 months
Volatility	45.90%	0.00%	45.14%	40.00%
Weighted average fair market value of grants	$ 5.54	$ 0	$ 4.93	$ 2.04

Equity-based compensation - Sto

Equity-based compensation - Stock Option Activity (Detail) - Stock Option [Member] - USD ($)	6 Months Ended
	Jul. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	5,055,505
Granted	1,220,259
Exercised	(51,836)
Forfeited and expired	(24,182)
Number of options outstanding and expected to vest	6,199,746
Exercisable	4,014,845
Amount vested at the end of the period	406,421
Weighted- average exercise price outstanding	$ 2.45
Granted	8.63
Exercised	1.51
Forfeited and expired	4.18
Weighted- average exercise price outstanding and expected to vest	3.66
Exercisable	1.98
Amount vested at the end of the period	$ 3.90
Weighted- average remaining contractual life outstanding and expected to vest	6 years 7 months 24 days
Weighted- average remaining contractual life exercisable	5 years 1 month 6 days
Aggregate intrinsic value outstanding and expected to vest	$ 50,628,007
Aggregate intrinsic value exercisable	$ 39,765,476

Equity-based compensation - Add

Equity-based compensation - Additional Information (Detail) - USD ($)	Jun. 20, 2019	Mar. 25, 2019	Oct. 14, 2014	Jun. 30, 2019	Jan. 31, 2019	Jan. 31, 2018	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value									$ 516,770	$ 555,453
Weighted average Term									3 years 2 months 12 days
Option plan expense							$ 653,016	$ 251,697	$ 1,242,065	$ 503,394
Unrecognized compensation cost to stock option							7,732,078		7,732,078
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date		2026-03
RSU's granted		390,794
Restricted stock expense							814,448		824,555
Unrecognised compensation costs							$ 3,700,364		$ 3,700,364
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		10.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		20.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		30.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		40.00%
Director [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date					2026-06
RSU's granted	58,589
2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options issued									151,548
Expiration date			2017-08
Number of shares available for issuance			4,424,986
2018 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized						3,048,490
2019 Stock Option And Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance				2,139,683
Percentage increase in number of shares reserved				5.00%
Percentage of vest option				25.00%
2019 Stock Option And Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
vesting term				4 years
2019 Stock Option And Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
vesting term				10 years
2019 Employee Stock Purchse Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance				855,873

Stock warrants - warrants to pu

Stock warrants - warrants to purchase common and preferred stock (Detail) - $ / shares	Jul. 31, 2019	Jan. 31, 2019
Preferred stock
Class of Warrant or Right [Line Items]
Number of warrants	0	1,636,641
Senior A Preferred | Exercise price 2.19, Expiration October 1, 2021
Class of Warrant or Right [Line Items]
Number of warrants	0	116,232
Exercise price		$ 2.19
Exercise price Expiration		Oct. 1, 2021
Senior A Preferred | Exercise price 3.00, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	0	672,560
Exercise price		$ 3
Exercise price Expiration		Nov. 1, 2026
Junior Preferred | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants	0	489,605
Exercise price		$ 0.01
Exercise price Expiration		Sep. 5, 2020
Redeemable Preferred | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants		358,244
Exercise price		$ 0.01
Exercise price Expiration		Sep. 5, 2020
Common stock
Class of Warrant or Right [Line Items]
Number of warrants	303,315	256,411
Common stock | Exercise price 2.02, Expiration October 21, 2025
Class of Warrant or Right [Line Items]
Number of warrants	0	166,952
Exercise price		$ 2.02
Exercise price Expiration		Oct. 21, 2025
Common stock | Exercise price 3.49, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	0	89,459
Exercise price		$ 3.49
Exercise price Expiration		Nov. 1, 2026
Common stock | Exercise price 8.02, Expiration February 28, 2029
Class of Warrant or Right [Line Items]
Number of warrants	150,274	0
Exercise price	$ 8.02
Exercise price Expiration	Feb. 28, 2029
Common stock (converted from preferred stock warrants) | Exercise price 6.59, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	153,041	0
Exercise price	$ 6.59
Exercise price Expiration	Nov. 1, 2026

Stock warrants - Activity for t

Stock warrants - Activity for the Company's warrants (Detail)	6 Months Ended
	Jul. 31, 2019shares
Common Stock [Member]
Class of Warrant or Right [Line Items]
Beginning, balance	256,411
Granted	150,274
Conversion of preferred stock warrants to common stock warrants	581,798
Exercised	(685,168)
Ending, balance	303,315
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Beginning, balance	1,636,411
Exercised	(1,636,641)
Ending, balance	0

Stock warrants - Reconciliation

Stock warrants - Reconciliation of warrant liability (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Beginning, balance			$ 5,497,627
Change in fair value of stock warrants six months ended July 31, 2019	$ 2,883,851	$ 593,215	3,306,959	$ 884,168
Conversion of convertible preferred stock warrants			(8,804,586)
Ending, balance	$ 0		$ 0

Stock warrants - Additional inf

Stock warrants - Additional information (Detail) - USD ($)	1 Months Ended	6 Months Ended
	Jul. 31, 2019	Jul. 31, 2019	Jan. 31, 2019
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants	256,411
Common stock withheld	25,919
Common stock warrants outstanding	$ 0	$ 0	$ 5,497,627
Securities called by warrants	428,757	428,757
Convertible Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Common stock warrants outstanding	$ 153,041	$ 153,041
Common Stock [Member]
Class of Warrant or Right [Line Items]
Common stock warrants outstanding	$ 303,315	$ 303,315
Conversion of preferred stock warrants to common stock warrants		581,798
Warrant [Member]
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants	428,757
Common stock withheld	70,485

Fair value measurements - Sched

Fair value measurements - Schedule Of weighted-average to determine the fair value of warrants (Detail) - Black Scholes Model [Member] - $ / shares	1 Months Ended	6 Months Ended
	Jan. 31, 2019	Jul. 31, 2019
Redeemable Series A Preferred Stock [Member] | Fair Value Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share Price	$ 5.80
Exercise price	$ 2.88
Remaining term	7 years 3 days
Risk-free interest rate	2.60%
Expected volatility	45.10%
Dividend yield	0.00%
Redeemable Series A Preferred Stock [Member] | Fair Value Warrant Liability Member [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share Price		$ 18
Exercise price		$ 6.33
Remaining term		6 years 6 months 18 days
Risk-free interest rate		1.90%
Expected volatility		45.90%
Dividend yield		0.00%
Junior Preferred Stock [Member] | Fair Value Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share Price	$ 4.88
Exercise price	$ 0.01
Remaining term	1 year 7 months 6 days
Risk-free interest rate	2.50%
Expected volatility	45.10%
Dividend yield	0.00%
Junior Preferred Stock [Member] | Fair Value Warrant Liability Member [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share Price		$ 18
Exercise price		$ 0.01
Remaining term		1 year 1 month 17 days
Risk-free interest rate		1.90%
Expected volatility		45.90%
Dividend yield		0.00%
Redeemable Preferred Stock [Member] | Fair Value Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share Price	$ 0.01
Exercise price	$ 0.01
Remaining term	1 year 7 months 6 days
Risk-free interest rate	2.50%
Expected volatility	45.10%
Dividend yield	0.00%

Fair value measurements - Addit

Fair value measurements - Additional Information (Detail) - USD ($)	Jul. 31, 2019	Jan. 31, 2019	Jul. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 0	$ 5,497,627
Fair value, assets, level 1 to level 2 transfers, amount	0		$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0		0
Fair value, liabilities, level 1 to level 2 transfers, amount	0		0
Fair value, liabilities, level 2 to level 1 transfers, amount	0		$ 0
Accounts Payable [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of foreign currency contracts	$ 21,093	$ 142,858

Commitments and contingencies -

Commitments and contingencies - Schedule of aggregate minimum net rental payments (Detail)	Jul. 31, 2019USD ($)
Commitments And Contingencies [Line Items]
2020 (Remaining six months)	$ 870,963
Year ending January 31, 2021	1,751,115
Year ending January 31, 2022	744,894
Year ending January 31, 2023	224,532
Total operating lease payments	$ 3,591,504

Commitments and contingencies_2

Commitments and contingencies - Schedule of minimum lease payments (Detail) - USD ($)	Jul. 31, 2019	Jan. 31, 2019
Commitments And Contingencies [Line Items]
2020 (Remaining six months)	$ 1,157,957
Year ending January 31, 2021	2,319,143
Year ending January 31, 2022	1,536,429
Year ending January 31, 2023	138,054
Total capital lease payments	5,151,583
Less amounts representing interest	(535,292)
Total capital lease payments, net of interest	4,616,291
Less current portion	(2,317,529)	$ (1,869,343)
Total capital lease payments, net of interest and current portion	$ 2,298,762	$ 2,401,104

Commitments and contingencies_3

Commitments and contingencies - Additional information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Commitments And Contingencies [Line Items]
Operating lease rent expense	$ 458,732	$ 449,630	$ 910,188	$ 896,994
Capital lease interest expense	$ 88,080	$ 61,097	$ 151,050	$ 110,070
Maximum [Member]
Commitments And Contingencies [Line Items]
Lease period	36 months		36 months
Minimum [Member]
Commitments And Contingencies [Line Items]
Lease period	30 months		30 months

Income taxes - Additional infor

Income taxes - Additional information (Detail)	6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%	0.00%
U.S. statutory tax rate	21.00%

Net loss per share attributab_3

Net loss per share attributable to common stockholders - Schedule of earnings per share basic and diluted (Detail) - USD ($)	3 Months Ended				6 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2018	Apr. 30, 2018	Jul. 31, 2019	Jul. 31, 2018
Numerator:
Net loss	$ (7,493,191)	$ (6,694,609)	$ (2,586,950)	$ (3,223,531)	$ (14,187,800)	$ (5,810,481)
Preferred stock dividend paid	(14,955,101)		0		(14,955,101)	0
Accretion of redeemable preferred stock	(48,311,988)		(9,236,353)		(56,175,418)	(11,726,050)
Net loss attributable to common stockholders	$ (70,760,280)		$ (11,823,303)		$ (85,318,319)	$ (17,536,531)
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted	6,793,363		1,776,559		4,443,155	1,755,268
Net loss attributable to common stockholders, basic and diluted	$ (10.42)		$ (6.66)		$ (19.20)	$ (9.99)

Net loss per share attributab_4

Net loss per share attributable to common stockholders - Schedule of antidilutive securities excluded from computation of earnings per share (Detail) - shares	6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,952,444	31,239,718
Redeemable convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	25,311,535
Stock options to purchase common stock and restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,649,129	5,089,974
Warrants to purchase convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	581,798
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	303,315	256,411

Related party transactions - Ad

Related party transactions - Additional Information (Detail) - Affiliated Entity [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018	Jan. 31, 2019
Related Party Transaction [Line Items]
Recognized revenue	$ 1,372,000	$ 1,219,000	$ 2,876,000	$ 2,578,000
Accounts receivable	$ 891,000		$ 891,000		$ 598,000